Louis Garguilo
ARTICLES BY LOUIS
-
![Garguilo_Photo_2015]( "Misjudging Leadership In the BioPharma Industry")
2/13/2015We can learn about leadership from Lego. Or rather, this plastic building-block company can show us how little we actually understand the subject.
-
![pharma CDMO revenue]( "Profit For Good At Rottendorf Pharmaceuticals")
2/10/2015The desire to work for a larger cause, to somehow apply whatever we do for a living to benefit society, continues to rise. And that desire can also elevate company revenues.
-
![Garguilo_Photo_2015]( "Pfizer Acquires Hospira: Biosimilars Gain Full Pharma Acceptance")
2/5/2015Just days after Outsourced Pharma’s in-depth, two-part article on Hospira and the role of biosimilars in global healthcare, and in which I asked Hospira’s Sumant Ramachandra whether he foresaw a future where a Pfizer comes to Hospira to work together on biosimilars, we have a definitive answer.
-
![Biosimilars Part 2: It’s All About Dollars Now]( "Biosimilars Part 2: It's All About Dollars Now")
2/2/2015Time to table the discussion on the science of replicating biologics. It’s all about dollars now. Part two of our look at biosimilars in the U.S.
-
![Biosimilars: A Brief Manifesto of Morality And Markets]( "Biosimilars: A Brief Manifesto of Morality And Markets")
1/26/2015As best I can describe it, here's an ideology for biosimilars in the U.S. healthcare system, from Sumant Ramachandra, executive and scientist at Hospira, Inc.
-
![Garguilo_Photo_2015]( "The Doctor Is In At Aptuit, But Needs To Hang A New Shingle")
1/12/2015Surveying the biopharma service provider landscape at the New Year, a piece turned up missing … A frank discussion with CEO Jonathan Goldman.
-
![Garguilo_Photo_2015]( "A Happy 2015 For Biopharma Industry? Put It In The Contract")
1/6/2015Is it too early to move from confetti to contracts? Perhaps, so let’s ease into one of 2015’s most important topics: the contracting ecosystem that now makes up the global biopharmaceutical industry.
-
![Garguilo_Photo_2015]( "Employment A Leading Indicator For Pharma Industry")
12/22/20142014 saw the continuation of many trends. But the one variable that most affects individuals and demonstrates industry strength or weakness is the ebb-and-flow of employment.
-
![Garguilo_Photo_2015]( "Biopharma Outsourcing Shall Be Revealed")
12/16/2014Pharmaceutical and biotechnology (biopharma) outsourcing is an unknown quantity to the global healthcare consumer. This will change and the biopharma industry ought to get in front of it.
-
![Garguilo_Photo_2015]( "Place Matters In A Global Pharmaceutical Industry")
12/5/2014Organizations gain competitive advantage if they integrate aspects of “place” by moving from the local geographic to a global overview, and from the functional to the psychological aspects associated with both realms.
Louis Garguilo
Click here to e-mail Louis
Louis Garguilo is chief editor of Outsourced Pharma, and is considered a leading authority on the art and science of drug development and manufacturing outsourcing. He studied public relations and journalism at Syracuse University (and holds a Master’s in English). His widely read editorials are based on in-depth analysis and interviews with industry executives and professionals. Editorials are written in an engaging and unique style that guide readers through the macro aspects and subtle nuances of outsourcing, and working with contract development and manufacturing organizations (CDMOs). Garguilo also serves as moderator for the various Outsourced Pharma Live webinars held throughout the year.
Prior to joining Outsourced Pharma in 2014, Garguilo spent a decade at a global pharmaceutical contract research, development and manufacturing organization, leaving the industry after attaining the role of vice president, business development and marketing. Additionally, he has served under the governor of New York in the state’s economic development agency, as liaison to the pharmaceutical/biotechnology industry; as chief strategic officer for an e-learning software company; and spent most of the ‘80s and ‘90s in Japan as an educator, author, and communications consultant.